August 12, 2025Neuro-Oncology AdvancesOpen Access

Mmap-17 Management of Melanoma Brain Metastases With Ipilimumab and Nivolumab With or Without Upfront Comprehensive Stereotactic Radiosurgery

View Full Paper

Ask AI

Bookmark

Patients receiving upfront stereotactic radiosurgery had longer intracranial progression-free survival at 16.8 months compared to 5.5 months without it.
Overall survival remained similar across groups at a median of 47 months, regardless of treatment approach with stereotactic radiosurgery or not.
The study analyzed 132 patients with newly diagnosed melanoma brain metastases, observing treatment responses to ipilimumab and nivolumab.
Results showed that symptoms and characteristics of brain metastases varied with treatment, highlighting the importance of careful patient selection.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study shows intracranial progression-free survival improves with upfront stereotactic radiosurgery in patients with melanoma brain metastases, indicating relevant treatment considerations.

Cite This Study

Kleber et al. (2025) studied this question.

synapsesocial.com/papers/68a3633d0a429f7973329fcc https://doi.org/10.1093/noajnl/vdaf123.056

View Full Paper

Ask AI

Bookmark

Mmap-17 Management of Melanoma Brain Metastases With Ipilimumab and Nivolumab With or Without Upfront Comprehensive Stereotactic Radiosurgery

Key Points

Discussion

Implication

Cite This Study

Mmap-17 Management of Melanoma Brain Metastases With Ipilimumab and Nivolumab With or Without Upfront Comprehensive Stereotactic Radiosurgery

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider